CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: bladder cancer</title> <meta name="description" content="Search results for: bladder cancer"> <meta name="keywords" content="bladder cancer"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="bladder cancer" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="bladder cancer"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 2180</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: bladder cancer</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2180</span> Diagnostic Evaluation of Urinary Angiogenin (ANG) and Clusterin (CLU) as Biomarker for Bladder Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Marwa%20I.%20Shabayek">Marwa I. Shabayek</a>, <a href="https://publications.waset.org/abstracts/search?q=Ola%20A.%20Said"> Ola A. Said</a>, <a href="https://publications.waset.org/abstracts/search?q=Hanan%20A.%20Attaia"> Hanan A. Attaia</a>, <a href="https://publications.waset.org/abstracts/search?q=Heba%20A.%20Awida"> Heba A. Awida</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Bladder carcinoma is an important worldwide health problem. Both cystoscopy and urine cytology used in detecting bladder cancer suffer from drawbacks where cystoscopy is an invasive method and urine cytology shows low sensitivity in low grade tumors. This study validates easier and less time-consuming techniques to evaluate the value of combined use of angiogenin and clusterin in comparison and combination with voided urine cytology in the detection of bladder cancer patients. This study includes malignant (bladder cancer patients, n= 50), benign (n=20), and healthy (n=20) groups. The studied groups were subjected to cystoscopic examination, detection of bilharzial antibodies, urine cytology, and estimation of urinary angiogenin and clusterin by ELISA. The overall sensitivity and specifcity were 66% and 75% for angiogenin, 70% and 82.5% for clusterin and 46% and 80% for voided urine cytology. Combined sensitivity of angiogenin and clusterin with urine cytology increased from 82 to 88%. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=angiogenin" title="angiogenin">angiogenin</a>, <a href="https://publications.waset.org/abstracts/search?q=bladder%20cancer" title=" bladder cancer"> bladder cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=clusterin" title=" clusterin"> clusterin</a>, <a href="https://publications.waset.org/abstracts/search?q=cytology" title=" cytology"> cytology</a> </p> <a href="https://publications.waset.org/abstracts/1844/diagnostic-evaluation-of-urinary-angiogenin-ang-and-clusterin-clu-as-biomarker-for-bladder-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/1844.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">297</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2179</span> The Anti-Bladder Cancer Effects Exerted by Hyaluronan Nanoparticles Encapsulated Heteronemin Isolated from Hippospongia Sp.</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Kuan%20Yin%20Hsiao">Kuan Yin Hsiao</a>, <a href="https://publications.waset.org/abstracts/search?q=Shyh%20Ming%20Kuo"> Shyh Ming Kuo</a>, <a href="https://publications.waset.org/abstracts/search?q=Yi%20Jhen%20Wu"> Yi Jhen Wu</a>, <a href="https://publications.waset.org/abstracts/search?q=Chin%20Wen%20Chuang"> Chin Wen Chuang</a>, <a href="https://publications.waset.org/abstracts/search?q=Chuen-Fu%20Lin"> Chuen-Fu Lin</a>, <a href="https://publications.waset.org/abstracts/search?q=Wei-qing%20Yang"> Wei-qing Yang</a>, <a href="https://publications.waset.org/abstracts/search?q=Han%0D%0AHsiang%20Huang"> Han Hsiang Huang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Anti-tumor effects of natural products, like compounds from marine sponges and soft corals, have been investigated for decades. Polymeric nanoparticles prepared from biodegradable and biocompatible molecules, such as Hyaluronan (HA), Chitosan (CHI) and gelatin have been widely studied. Encapsulation of anti-cancer therapies by the biopolymeric nanoparticles in drug delivery system is potentially capable of improving the therapeutic effects and attenuating their toxicity. In the current study, the anti-bladder cancer effects of heteronemin extracted from the sponge Hippospongia sp. with or without HA and CHI nanoparticle encapsulation were assessed and evaluated in vitro. Results showed that IC50 (half maximal inhibitory concentration) of heteronemin toward T24 human bladder cancer cell viability is approximately 0.18 µg/mL. Both plain and HA nanoparticles-encapsulated heteronemin at 0.2 and 0.4 µg/mL significantly reduced T24 cell viability (P<0.001) while HA nanoparticles-encapsulated heteronemin showed weaker viability-inhibitory effects on L929 fibroblasts compared with plain heteronemin at the identical concentrations. HA and CHI nanoparticles-encapsulated heteronemin exhibited significantly stronger inhibitory effects against migration of T24 human bladder cancer cell than those exerted by plain heteronemin at the same concentrations (P<0.001). The flow cytometric results showed that 0.2 µg/mL HA and CHI nanoparticles-encapsulated heteronemin induced higher early apoptosis rate than that induced by plain heteronemin at the same concentration. These results show that HA and CHI nanoparticle encapsulation is able to elevate anti-migratory and apoptosis-inducing effects exerted by heteronemin against bladder cancer cells in vitro. The in vivo anti-bladder cancer effects of the compound with or without HA/CHI nanoparticle encapsulation will be further investigated and examined using murine tumor models. The data obtained from this study will extensively evaluate of the anti-bladder cancer effects of heteronemin as well as HA/CHI-encapsulated heteronemin and pave a way to develop potential bladder cancer treatment. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=heteronemin" title="heteronemin">heteronemin</a>, <a href="https://publications.waset.org/abstracts/search?q=nanoparticles" title=" nanoparticles"> nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=hyaluronan" title=" hyaluronan"> hyaluronan</a>, <a href="https://publications.waset.org/abstracts/search?q=chitosan" title=" chitosan"> chitosan</a>, <a href="https://publications.waset.org/abstracts/search?q=bladder%20cancer" title=" bladder cancer "> bladder cancer </a> </p> <a href="https://publications.waset.org/abstracts/30517/the-anti-bladder-cancer-effects-exerted-by-hyaluronan-nanoparticles-encapsulated-heteronemin-isolated-from-hippospongia-sp" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/30517.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">456</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2178</span> Autophagy Suppresses Bladder Tumor Formation in a Mouse Orthotopic Bladder Tumor Formation Model</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Wan-Ting%20Kuo">Wan-Ting Kuo</a>, <a href="https://publications.waset.org/abstracts/search?q=Yi-Wen%20Liu"> Yi-Wen Liu</a>, <a href="https://publications.waset.org/abstracts/search?q=Hsiao-Sheng%20Liu"> Hsiao-Sheng Liu</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Annual incidence of bladder cancer increases in the world and occurs frequently in the male. Most common type is transitional cell carcinoma (TCC) which is treated by transurethral resection followed by intravesical administration of agents. In clinical treatment of bladder cancer, chemotherapeutic drugs-induced apoptosis is always used in patients. However, cancers usually develop resistance to chemotherapeutic drugs and often lead to aggressive tumors with worse clinical outcomes. Approximate 70% TCC recurs and 30% recurrent tumors progress to high-grade invasive tumors, indicating that new therapeutic agents are urgently needed to improve the successful rate of overall treatment. Nonapoptotic program cell death may assist to overcome worse clinical outcomes. Autophagy which is one of the nonapoptotic pathways provides another option for bladder cancer patients. Autophagy is reported as a potent anticancer therapy in some cancers. First of all, we established a mouse orthotopic bladder tumor formation model in order to create a similar tumor microenvironment. IVIS system and micro-ultrasound were utilized to noninvasively monitor tumor formation. In addition, we carried out intravesical treatment in our animal model to be consistent with human clinical treatment. In our study, we carried out intravesical instillation of the autophagy inducer in mouse orthotopic bladder tumor to observe tumor formation by noninvasive IVIS system and micro-ultrasound. Our results showed that bladder tumor formation is suppressed by the autophagy inducer, and there are no significant side effects in the physiology of mice. Furthermore, the autophagy inducer upregulated autophagy in bladder tissues of the treated mice was confirmed by Western blot, immunohistochemistry, and immunofluorescence. In conclusion, we reveal that a novel autophagy inducer with low side effects suppresses bladder tumor formation in our mouse orthotopic bladder tumor model, and it provides another therapeutic approach in bladder cancer patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=bladder%20cancer" title="bladder cancer">bladder cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=transitional%20cell%20carcinoma" title=" transitional cell carcinoma"> transitional cell carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=orthotopic%20bladder%20tumor%20formation%20model" title=" orthotopic bladder tumor formation model"> orthotopic bladder tumor formation model</a>, <a href="https://publications.waset.org/abstracts/search?q=autophagy" title=" autophagy"> autophagy</a> </p> <a href="https://publications.waset.org/abstracts/56139/autophagy-suppresses-bladder-tumor-formation-in-a-mouse-orthotopic-bladder-tumor-formation-model" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/56139.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">176</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2177</span> Development of Programmed Cell Death Protein 1 Pathway-Associated Prognostic Biomarkers for Bladder Cancer Using Transcriptomic Databases</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Shu-Pin%20Huang">Shu-Pin Huang</a>, <a href="https://publications.waset.org/abstracts/search?q=Pai-Chi%20Teng"> Pai-Chi Teng</a>, <a href="https://publications.waset.org/abstracts/search?q=Hao-Han%20Chang"> Hao-Han Chang</a>, <a href="https://publications.waset.org/abstracts/search?q=Chia-Hsin%20Liu"> Chia-Hsin Liu</a>, <a href="https://publications.waset.org/abstracts/search?q=Yung-Lun%20Lin"> Yung-Lun Lin</a>, <a href="https://publications.waset.org/abstracts/search?q=Shu-Chi%20Wang"> Shu-Chi Wang</a>, <a href="https://publications.waset.org/abstracts/search?q=Hsin-Chih%20Yeh"> Hsin-Chih Yeh</a>, <a href="https://publications.waset.org/abstracts/search?q=Chih-Pin%20Chuu"> Chih-Pin Chuu</a>, <a href="https://publications.waset.org/abstracts/search?q=Jiun-Hung%20Geng"> Jiun-Hung Geng</a>, <a href="https://publications.waset.org/abstracts/search?q=Li-Hsin%20Chang"> Li-Hsin Chang</a>, <a href="https://publications.waset.org/abstracts/search?q=Wei-Chung%20Cheng"> Wei-Chung Cheng</a>, <a href="https://publications.waset.org/abstracts/search?q=Chia-Yang%20Li"> Chia-Yang Li</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The emergence of immune checkpoint inhibitors (ICIs) targeting proteins like PD-1 and PD-L1 has changed the treatment paradigm of bladder cancer. However, not all patients benefit from ICIs, with some experiencing early death. There's a significant need for biomarkers associated with the PD-1 pathway in bladder cancer. Current biomarkers focus on tumor PD-L1 expression, but a more comprehensive understanding of PD-1-related biology is needed. Our study has developed a seven-gene risk score panel, employing a comprehensive bioinformatics strategy, which could serve as a potential prognostic and predictive biomarker for bladder cancer. This panel incorporates the FYN, GRAP2, TRIB3, MAP3K8, AKT3, CD274, and CD80 genes. Additionally, we examined the relationship between this panel and immune cell function, utilizing validated tools such as ESTIMATE, TIDE, and CIBERSORT. Our seven-genes panel has been found to be significantly associated with bladder cancer survival in two independent cohorts. The panel was also significantly correlated with tumor infiltration lymphocytes, immune scores, and tumor purity. These factors have been previously reported to have clinical implications on ICIs. The findings suggest the potential of a PD-1 pathway-based transcriptomic panel as a prognostic and predictive biomarker in bladder cancer, which could help optimize treatment strategies and improve patient outcomes. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=bladder%20cancer" title="bladder cancer">bladder cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=programmed%20cell%20death%20protein%201" title=" programmed cell death protein 1"> programmed cell death protein 1</a>, <a href="https://publications.waset.org/abstracts/search?q=prognostic%20biomarker" title=" prognostic biomarker"> prognostic biomarker</a>, <a href="https://publications.waset.org/abstracts/search?q=immune%20checkpoint%20inhibitors" title=" immune checkpoint inhibitors"> immune checkpoint inhibitors</a>, <a href="https://publications.waset.org/abstracts/search?q=predictive%20biomarker" title=" predictive biomarker"> predictive biomarker</a> </p> <a href="https://publications.waset.org/abstracts/173666/development-of-programmed-cell-death-protein-1-pathway-associated-prognostic-biomarkers-for-bladder-cancer-using-transcriptomic-databases" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/173666.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">78</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2176</span> An Unusual Presentation of Plasmacytoid Urothelial Carcinoma of the Bladder - A Case Report and Literature Review</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Bharti%20Arora">Bharti Arora</a>, <a href="https://publications.waset.org/abstracts/search?q=Michael%20Chen"> Michael Chen</a>, <a href="https://publications.waset.org/abstracts/search?q=Steven%20Lun"> Steven Lun</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Plasmacytoid urothelial carcinoma (PUC) of the bladder is a rare and aggressive subtype of urothelial carcinoma that usually presents at an advanced clinical stage, has a predilection for early metastatic potential and is associated with poor prognosis. The first reported case of PUC was in 1991 and approximately 100 cases were reported in the literature worldwide. We present a case of a 43 year old female presenting with a 3-month history of urgency and frequency. Failing medical management of her urinary symptoms with anticholinergic medication, she underwent a diagnostic cystoscopy which revealed an erythematous and indurated bladder. Bladder biopsies of these regions revealed plasmacytoid urothelial carcinoma. Pre-operative staging scans were clear of any metastatic disease and the patient subsequently underwent a radical cystectomy and pelvic clearance with the formation of ileal conduit for urinary diversion. Histology confirmed plasmacytoid urothelial carcinoma with involvement of right upper vagina and focally positive margins in soft tissue at right and left sides of bladder. She received adjuvant chemotherapy but passed away within a year from disease progression. PUC can present atypically and our case highlights the role of cystoscopy in patients with persistent urinary symptoms. By reviewing the literature on PUC, we aim to raise awareness and improve understanding of this rare bladder cancer subtype amongst urologists. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=urology" title="urology">urology</a>, <a href="https://publications.waset.org/abstracts/search?q=bladder%20cancer" title=" bladder cancer"> bladder cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=plasmacytoid%20urothelial%20cancer" title=" plasmacytoid urothelial cancer"> plasmacytoid urothelial cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=literature%20review" title=" literature review"> literature review</a> </p> <a href="https://publications.waset.org/abstracts/142561/an-unusual-presentation-of-plasmacytoid-urothelial-carcinoma-of-the-bladder-a-case-report-and-literature-review" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/142561.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">150</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2175</span> Effect of Diindolylmethane on BBN-Induced Bladder Carcinogenesis in Rats</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sundaresan%20Sivapatham">Sundaresan Sivapatham</a>, <a href="https://publications.waset.org/abstracts/search?q=B.%20Prabhu"> B. Prabhu</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Cancer results from a multistage, multi-mechanism carcinogenesis process that involves mutagenic, cell death and epigenetic mechanisms, during the three distinguishable but closely allied stages: initiation, promotion, and progression. Chemoprevention is promising in the realm of cancer prevention and it has been shown to reduce the risk of development of carcinoma in highly susceptible individuals such as those with known genetic mutations or high level of risk factors. The present study is aimed at the need of early detection of bladder cancer in order to improve performance in the treatment of this disease. Consumption of certain natural products like DIM is associated with a reduction in cancer incidence in humans. The study showed the protective effects of Diindolylmethane in N-Butyl-N-(4-hydroxybutyl) nitrosamine treated rats. Results of the study had shown the changes in the tumor markers, biomarkers and histopathological alterations in experimental rats when compared to control rats. The protective effects of DIM were shown from the results of cell proliferation, apoptotic markers and histopathological findings when compared with experimental control animals. Hence, our results speculate that the tumor markers, apoptotic markers, histopathological changes and cell proliferation index measured as PCNA serves as an indicator suggestive of protective effects of DIM in BBN induced urinary bladder carcinogenesis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=bladder%20cancer" title="bladder cancer">bladder cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=N-Butyl-N-%284-hydroxybutyl%29%20nitrosamine" title=" N-Butyl-N-(4-hydroxybutyl) nitrosamine"> N-Butyl-N-(4-hydroxybutyl) nitrosamine</a>, <a href="https://publications.waset.org/abstracts/search?q=diindolylmethane" title=" diindolylmethane"> diindolylmethane</a>, <a href="https://publications.waset.org/abstracts/search?q=histopathology" title=" histopathology"> histopathology</a> </p> <a href="https://publications.waset.org/abstracts/37513/effect-of-diindolylmethane-on-bbn-induced-bladder-carcinogenesis-in-rats" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/37513.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">342</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2174</span> Endometriosis, Bladder Endometriosis (BE), Urinary Tract Endometriosis (UTE), Robotic-Assisted Surgery</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Farida%20Eid">Farida Eid</a>, <a href="https://publications.waset.org/abstracts/search?q=Hala%20Nasseif"> Hala Nasseif</a>, <a href="https://publications.waset.org/abstracts/search?q=Hana%20Mokhtar"> Hana Mokhtar</a>, <a href="https://publications.waset.org/abstracts/search?q=Labib%20Riachi"> Labib Riachi</a>, <a href="https://publications.waset.org/abstracts/search?q=Mudhar%20Hasan"> Mudhar Hasan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Bladder Endometriosis is a rare form of endometriosis and is defined as the presence of endometriotic tissue in the detrusor muscle of the bladder, either in full or partial thickness. Women typically present with dysuria, urinary frequency, hematuria, and recurrent urinary tract infections. Bladder endometriosis is typically found at the bladder base and bladder dome. Transvaginal ultrasound is considered first-line imaging, and the condition is typically managed with laparoscopic partial cystectomy. A 33-year-old nulliparous woman presented with chronic pelvic pain, severe dysmenorrhea, and metrorrhagia. The patient was previously diagnosed with bladder endometriomas two years ago with multiple recurrences. MRI revealed urinary bladder endometriosis measuring 3 x 2 x 1.5 cm. Accordingly, the patient underwent a cystoscopy-guided robotic-assisted excision of the endometriotic implant in the bladder with cystotomy and repair of the bladder mucosa. The operation was tolerated well, and the postoperative period was uneventful. Bladder Endometriosis (BE) typically presents with urinary symptoms and can be mistaken for a bladder tumor upon further imaging. The case was successfully managed with cystoscopy-guided, robotic-assisted excision and fulguration of the endometriotic implant in the bladder. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=endometriosis" title="endometriosis">endometriosis</a>, <a href="https://publications.waset.org/abstracts/search?q=bladder%20endometriosis%20%28BE%29" title=" bladder endometriosis (BE)"> bladder endometriosis (BE)</a>, <a href="https://publications.waset.org/abstracts/search?q=urinary%20tract%20endometriosis%20%28UTE%29" title=" urinary tract endometriosis (UTE)"> urinary tract endometriosis (UTE)</a>, <a href="https://publications.waset.org/abstracts/search?q=robotic-assisted%20surgery" title=" robotic-assisted surgery"> robotic-assisted surgery</a> </p> <a href="https://publications.waset.org/abstracts/189818/endometriosis-bladder-endometriosis-be-urinary-tract-endometriosis-ute-robotic-assisted-surgery" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/189818.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">29</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2173</span> An Audit of Restaging Transurethral Resection of Bladder Tumor (Re-TURBT) Quality in a District General Hospital</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rizwan%20Iqbal">Rizwan Iqbal</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Re-TURBT has been recommended by international guidelines for patients with non-muscle invasive bladder cancer (NMIBC) who are deemed high-risk. Indications for re-TURBTs remain controversial and studies show mixed outcomes. It should be performed when the initial TURBT specimen lacks detrusor muscle, has tumor stage pT1 or G3/high-grade, or where resection is deemed incomplete. This ensures complete resection of tumors that have a high risk of recurrence as well as accurately identifying any tumors which have been upstaged. The aim of this audit was to evaluate the quality of re-TURBTs in a district general hospital. Method: Data were retrospectively collected from 31 patients who had re-TURBTs between April 2021 and September 2022. Data included baseline demographics, time from initial to re-TURBT, quality of operation note, presence of residual tumor, complications, and administration of chemotherapy within 24 hours of the initial TURBT. Data collection remains ongoing at the time of writing. Results: The mean age was 76 years old and 71.0% of patients were male. 32.3% of patients had their re-TURBT within six weeks and 32.3% had intravesical chemotherapy administered within 24 hours of the initial TURBT. 74.2% of initial TURBTs had detrusor muscle present in the specimen. 48.4% of patients had residual disease following re-TURBT. Just one patient had their pathology upstaged at re-TURBT. The use of the TURBT proforma on the operation note was variable, with 51.6% and 38.7% of surgeons using the proforma after the initial and re-TURBT. Conclusion: Re-TURBT improves bladder cancer staging and is necessary in patients who are deemed high-risk in order to identify any upstaging or recurrence of the disease. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=urology" title="urology">urology</a>, <a href="https://publications.waset.org/abstracts/search?q=bladder%20cancer" title=" bladder cancer"> bladder cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=turbt" title=" turbt"> turbt</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer" title=" cancer"> cancer</a> </p> <a href="https://publications.waset.org/abstracts/163102/an-audit-of-restaging-transurethral-resection-of-bladder-tumor-re-turbt-quality-in-a-district-general-hospital" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/163102.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">62</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2172</span> Comparison of the Dose Reached to the Rectum and Bladder in Two Treatment Methods by Tandem and Ovoid and Tandem and Ring in the High Dose Rate Brachytherapy of Cervical Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Akbar%20Haghzadeh%20Saraskanroud">Akbar Haghzadeh Saraskanroud</a>, <a href="https://publications.waset.org/abstracts/search?q=Amir%20Hossein%20Yahyavi%20Zanjani"> Amir Hossein Yahyavi Zanjani</a>, <a href="https://publications.waset.org/abstracts/search?q=Niloofar%20Kargar"> Niloofar Kargar</a>, <a href="https://publications.waset.org/abstracts/search?q=Hanieh%20Ahrabi"> Hanieh Ahrabi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Cervical cancer refers to an unusual growth of cells in the cervix. The cervix is the lower part of the uterus, which connects to the vagina. Various risk factors such as human papillomavirus (HPV), having a weakened immune system, smoking or breathing in secondhand smoke, reproductive factors, and obesity play important roles in causing most cervical cancers. When cervical cancer happens, surgery is often the first treatment option to remove it. Other treatments might include chemotherapy and targeted therapy medicines. Radiation therapy with high-energy photon beams also may be used. Sometimes combined treatment, including radiation with low-dose chemotherapy, was applied. Intracavitary brachytherapy is an integral part of radiotherapy for locally advanced gynecologic malignancies such as cervical cancer. In the treatment of cervical cancer, there are different tools for doing brachytherapy. Two combinations of different applicators for this purpose are Tandem and Ovoid and Tandem and Ring. This study evaluated the dose differences between these two methods in the organs at risk of the rectum, sigmoid, and bladder. In this study, the treatment planswere simulated by the Oncentra treatment planning system and Tandem, Ovid, and Rings of different sizes. CT scan images of 23 patients were treated with HDR_BT Elekta Flexitron system were used for this study. Contouring of HR-CTV, rectum and bladder was performed for all patients. Then, the received dose of 0.1 and 0.2cc volumes of organs at risk were obtained and compared for these two methods: T-Ovoid and T-Ring. By doing investigations and dose measurements of points A and B and the volumes specified by ICRU, it seems that when comparing ring and ovoid to tandem and ovoid, the total dose to the rectum was lower by about 11%, and the bladder was 7%. In the case of HR CTV, this comparison showed that this ratio is about 7% better. Figure 1 shows the amount of decrease in rectum dose in the T-Ring method compared to T-Ovoid. Figure 2 indicates the amount of decrease in bladder dose in the T-Ring method compared to T-Ovoid. Finally, figure 3 illustrates the amount of HR-CTV coverage in the T-Ring method compared to the T-Ovoid. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cervical%20cancer" title="cervical cancer">cervical cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=brachytherapy" title=" brachytherapy"> brachytherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=rectum" title=" rectum"> rectum</a>, <a href="https://publications.waset.org/abstracts/search?q=tandem%20and%20ovoid" title=" tandem and ovoid"> tandem and ovoid</a>, <a href="https://publications.waset.org/abstracts/search?q=tandem%20and%20ring." title=" tandem and ring."> tandem and ring.</a> </p> <a href="https://publications.waset.org/abstracts/187948/comparison-of-the-dose-reached-to-the-rectum-and-bladder-in-two-treatment-methods-by-tandem-and-ovoid-and-tandem-and-ring-in-the-high-dose-rate-brachytherapy-of-cervical-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/187948.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">42</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2171</span> Clinical Value of 18F-FDG-PET Compared with CT Scan in the Detection of Nodal and Distant Metastasis in Urothelial Carcinoma or Bladder Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohammed%20Al-Zubaidi">Mohammed Al-Zubaidi</a>, <a href="https://publications.waset.org/abstracts/search?q=Katherine%20Ong"> Katherine Ong</a>, <a href="https://publications.waset.org/abstracts/search?q=Pravin%20Viswambaram"> Pravin Viswambaram</a>, <a href="https://publications.waset.org/abstracts/search?q=Steve%20McCombie"> Steve McCombie</a>, <a href="https://publications.waset.org/abstracts/search?q=Oliver%20Oey"> Oliver Oey</a>, <a href="https://publications.waset.org/abstracts/search?q=Jeremy%20Ong"> Jeremy Ong</a>, <a href="https://publications.waset.org/abstracts/search?q=Richard%20Gauci"> Richard Gauci</a>, <a href="https://publications.waset.org/abstracts/search?q=Ronny%20Low"> Ronny Low</a>, <a href="https://publications.waset.org/abstracts/search?q=Dickon%20Hayne"> Dickon Hayne</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Objective: Lymph node involvement along with distant metastasis in a patient with invasive bladder cancer determines the disease survival, therefeor, it is an essential determinant of the therapeutic management and outcome. This retrospective study aims to determine the accuracy of FDG PET scan in detecting lymphatic involvement and distant metastatic urothelial cancer compared to conventional CT staging. Method: A retrospective review of 76 patients with UC or BC who underwent surgery or confirmatory biopsy that was staged with both CT and 18F-FDG-PET (up to 8 weeks apart) between 2015 and 2020. Fifty-sevenpatients (75%) had formal pelvic LN dissection or biopsy of suspicious metastasis. 18F-FDG-PET reports for positive sites were qualitative depending on SUV Max. On the other hand, enlarged LN by RECIST criteria 1.1 (>10 mm) and other qualitative findings suggesting metastasis were considered positive in CT scan. Histopathological findings from surgical specimens or image-guided biopsies were considered the gold standard in comparison to imaging reports. 18F-FDG-avid or enlarged pelvic LNs with surgically proven nodal metastasis were considered true positives. Performance characteristics of 18F-FDG-PET and CT, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (PPV), were calculated. Results: Pelvic LN involvement was confirmed histologically in 10/57 (17.5%) patients. Sensitivity, specificity, PPV and NPV of CT for detecting pelvic LN metastases were 41.17% (95% CI:18-67%), 100% (95% CI:90-100%) 100% (95% CI:59-100%) and 78.26% (95% CI:64-89%) respectively. Sensitivity, specificity, PPV and NPV of 18F-FDG-PET for detecting pelvic LN metastases were 62.5% (95% CI:35-85%), 83.78% (95% CI:68-94%), 62.5% (95% CI:35-85%), and 83.78% (95% CI:68-94%) respectively. Pre-operative staging with 18F-FDG-PET identified the distant metastatic disease in 9/76 (11.8%) patients who were occult on CT. This retrospective study suggested that 18F-FDG-PET may be more sensitive than CT for detecting pelvic LN metastases. 7/76 (9.2%) patients avoided cystectomy due to 18F-FDG-PET diagnosed metastases that were not reported on CT. Conclusion: 18F-FDG-PET is more sensitive than CT for pelvic LN metastases, which can be used as the standard modality of bladder cancer staging, as it may change the treatment by detecting lymph node metastasis that was occult in CT. Further research involving randomised controlled trials comparing the diagnostic yield of 18F-FDG-PET and CT in detecting nodal and distant metastasis in UC or BC is warranted to confirm our findings. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=FDG%20PET" title="FDG PET">FDG PET</a>, <a href="https://publications.waset.org/abstracts/search?q=CT%20scan" title=" CT scan"> CT scan</a>, <a href="https://publications.waset.org/abstracts/search?q=urothelial%20cancer" title=" urothelial cancer"> urothelial cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=bladder%20cancer" title=" bladder cancer"> bladder cancer</a> </p> <a href="https://publications.waset.org/abstracts/154697/clinical-value-of-18f-fdg-pet-compared-with-ct-scan-in-the-detection-of-nodal-and-distant-metastasis-in-urothelial-carcinoma-or-bladder-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/154697.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">121</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2170</span> Evaluating Therapeutic Efficacy of Intravesical Xenogeneic Urothelial Cell Treatment Alone and in Combination with Chemotherapy or Immune Checkpoint Inhibitors in a Mouse Non-Muscle-Invasive Bladder Cancer Model</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Chih-Rong%20Shyr">Chih-Rong Shyr</a>, <a href="https://publications.waset.org/abstracts/search?q=Chi-Ping%20Huang"> Chi-Ping Huang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Intravesical BCG is the gold-standard therapy for high risk non-muscle invasive bladder cancer (NMIBC) after TURBT, but if not responsive to BCG, these BCG unresponsive patients face cystectomy that causes morbidity and comes with a morality risk. To provide the bladder sparing options for patients with BCG-unresponsive NMIBC, several new treatments have been developed to salvage the bladders and prevent progression to muscle invasive or metastatic, but however, most approved or developed treatments still fail in a significant proportion of patients without long term success. Thus more treatment options and the combination of different therapeutic modalities are urgently needed to change the outcomes. Xenogeneic rejection has been proposed to a mechanism of action to induce anti-tumor immunity for the treatment of cancers due to the similarities between rejection mechanism to xenoantigens (proteins, glycans and lipids) and anti-tumor immunities to tumor specific antigens (neoantigens, tumor associated carbohydrates and lipids). Xenogeneic urothelial cells (XUC) of porcine origin have been shown to induce anti-tumor immune responses to inhibit bladder tumor progression in mouse bladder cancer models. To further demonstrate the efficacy of the distinct intravesical XUC treatment in NMIBC, and the combined effects with chemotherapy and immune checkpoint inhibitors (ICIs) as a alternate therapeutic option, this study investigated the therapeutic effects and mechanisms of intravesical XUC immunotherapy in an orthotopic mouse immune competent model of NMIBC, generated from a mouse bladder cancer cell line. We found that the tumor progression was inhibited by intravescial XUC treatment and there was a synergy between intravesical XUC with intravesical chemotherapeutic agent, gemcitabine or systemic ICI, anti-PD1 antibody treatment. The cancer cell proliferation was decreased but the cell death was increased by the intravecisal XUC treatment. Most importantly, the mechanisms of action of intravesical XUC immunotherapy were found to be linked to enhanced infiltration of CD4+ and CD8+ T-cell as well as NK cells, but decreased presence of myeloid immunosuppressive cells in XUC treated tumors. The increased stimulation of immune cells of XUC treated mice to xenogeneic urothelial cells and mouse bladder cancer cells in immune cell proliferation and cytokine secretion were observed both as a monotherapy and in combination with intravesical gemcitabine or systemic anti PD-L1 treatment. In sum, we identified the effects of intravesical XUC treatment in monotherapy and combined therapy on tumor progression and its cellular and molecular events related to immune activation to understand the anti-tumoral mechanisms behind intravesical XUC immunotherapy for NMIBC. These results contribute to the understanding of the mechanisms behind successful xenogeneic cell immunotherapy against NMIBC and characterize a novel therapeutic approach with a new xenogeneic cell modality for BCG-unresponsive NMIBC. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=xenoantigen" title="xenoantigen">xenoantigen</a>, <a href="https://publications.waset.org/abstracts/search?q=neoantigen" title=" neoantigen"> neoantigen</a>, <a href="https://publications.waset.org/abstracts/search?q=rejection" title=" rejection"> rejection</a>, <a href="https://publications.waset.org/abstracts/search?q=immunity" title=" immunity"> immunity</a> </p> <a href="https://publications.waset.org/abstracts/194605/evaluating-therapeutic-efficacy-of-intravesical-xenogeneic-urothelial-cell-treatment-alone-and-in-combination-with-chemotherapy-or-immune-checkpoint-inhibitors-in-a-mouse-non-muscle-invasive-bladder-cancer-model" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/194605.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">6</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2169</span> A Literature Review on Bladder Management in Individuals with Spinal Cord Injury</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Elif%20Ates">Elif Ates</a>, <a href="https://publications.waset.org/abstracts/search?q=Naile%20Bilgili"> Naile Bilgili</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: One of the most important medical complications that individuals with spinal cord injury (SCI) face are the neurogenic bladder. Objectives: To review methods used for management of neurogenic bladder and their effects. Methods: The study was conducted by searching CINAHL, Ebscohost, MEDLINE, Science Direct, Ovid, ProQuest, Web of Science, and ULAKBİM National Databases for studies published between 2005 and 2015. Key words used during the search included ‘spinal cord injury’, ‘bladder injury’, ‘nursing care’, ‘catheterization’ and ‘intermittent urinary catheter’. After examination of 551 studies, 21 studies which met inclusion criteria were included in the review. Results: Mean age of individuals in all study samples was 42 years. The most commonly used bladder management method was clean intermittent catheterization (CIC). Compliance with CIC was found to be significantly related to spasticity, maximum cystometric capacity, and the person performing catheterization (p < .05). The main reason for changing the existing bladder management method was urinary tract infections (UTI). Individuals who performed CIC by themselves and who voided spontaneously had better life quality. Patient age, occupation status and whether they performed CIC by themselves or not were found to be significantly associated with depression level (p ≤ .05). Conclusion: As the most commonly used method for bladder management, CIC is a reliable and effective method, and reduces the risk of UTI development. Individuals with neurogenic bladder have a higher prevalence of depression symptoms than the normal population. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=bladder%20management" title="bladder management">bladder management</a>, <a href="https://publications.waset.org/abstracts/search?q=catheterization" title=" catheterization"> catheterization</a>, <a href="https://publications.waset.org/abstracts/search?q=nursing" title=" nursing"> nursing</a>, <a href="https://publications.waset.org/abstracts/search?q=spinal%20cord%20injury" title=" spinal cord injury"> spinal cord injury</a> </p> <a href="https://publications.waset.org/abstracts/74098/a-literature-review-on-bladder-management-in-individuals-with-spinal-cord-injury" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/74098.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">173</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2168</span> Biomechanical Perspectives on the Urinary Bladder: Insights from the Hydrostatic Skeleton Concept</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Igor%20Vishnevskyi">Igor Vishnevskyi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: The urinary bladder undergoes repeated strain during its working cycle, suggesting the presence of an efficient support system, force transmission, and mechanical amplification. The concept of a "hydrostatic skeleton" (HS) could contribute to our understanding of the functional relationships among bladder constituents. Methods: A multidisciplinary literature review was conducted to identify key features of the HS and to gather evidence supporting its applicability in urinary bladder biomechanics. The collected evidence was synthesized to propose a framework for understanding the potential hydrostatic properties of the urinary bladder based on existing knowledge and HS principles. Results: Our analysis revealed similarities in biomechanical features between living fluid-filled structures and the urinary bladder. These similarities include the geodesic arrangement of fibres, the role of enclosed fluid (urine) in force transmission, prestress as a determinant of stiffness, and the ability to maintain shape integrity during various activities. From a biomechanical perspective, urine may be considered an essential component of the bladder. The hydrostatic skeleton, with its autonomy and flexibility, may provide insights for researchers involved in bladder engineering. Discussion: The concept of a hydrostatic skeleton offers a holistic perspective for understanding bladder function by considering multiple mechanical factors as a single structure with emergent properties. Incorporating viewpoints from various fields on HS can help identify how this concept applies to live fluid-filled structures or organs and reveal its broader relevance to biological systems, both natural and artificial. Conclusion: The hydrostatic skeleton (HS) design principle can be applied to the urinary bladder. Understanding the bladder as a structure with HS can be instrumental in biomechanical modelling and engineering. Further research is required to fully elucidate the cellular and molecular mechanisms underlying HS in the bladder. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hydrostatic%20skeleton" title="hydrostatic skeleton">hydrostatic skeleton</a>, <a href="https://publications.waset.org/abstracts/search?q=urinary%20bladder%20morphology" title=" urinary bladder morphology"> urinary bladder morphology</a>, <a href="https://publications.waset.org/abstracts/search?q=shape%20integrity" title=" shape integrity"> shape integrity</a>, <a href="https://publications.waset.org/abstracts/search?q=prestress" title=" prestress"> prestress</a>, <a href="https://publications.waset.org/abstracts/search?q=biomechanical%20modelling" title=" biomechanical modelling"> biomechanical modelling</a> </p> <a href="https://publications.waset.org/abstracts/166783/biomechanical-perspectives-on-the-urinary-bladder-insights-from-the-hydrostatic-skeleton-concept" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/166783.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">78</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2167</span> Evaluation of the Radiolabelled 68GA-DOTATOC Complex in Adenocarcinoma Breast Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri">S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Naderi"> M. Naderi</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia"> H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=B.%20Alirzapour"> B. Alirzapour</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20R.%20Jalilian"> A. R. Jalilian</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Ramazani"> A. Ramazani </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Nowadays, 68Ga-DOTATOC has been known as a potential agent for the detection of neuroendocrine tumours and it has indicated higher sensitivity compared with the 111In-Octeroetide. The aim of this study was to evaluate the effectiveness of this new agent in the diagnosis of adenocarcinoma breast cancer. 68Ga-DOTATOC was prepared with the radiochemical purity of higher than 98% and by the specific activity of 39.6 TBq/mmol. 37 MBq of the complex was injected intravenously into the BULB/c mice with adenocarcinoma breast cancer. PET/CT images were acquired after 30, 60 and 90 min post injection demonstrated significant accumulation in the tumour sites. Also, considerable activity was observed in the kidney and bladder as the main routs of excretion. Generally, the results showed that 68Ga-DOTATOC can be considered as a suitable complex for diagnosis of the adenocarcinoma breast cancer using PET procedure. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=adenocarcinoma%20breast%20cancer" title="adenocarcinoma breast cancer">adenocarcinoma breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=68Ga" title=" 68Ga"> 68Ga</a>, <a href="https://publications.waset.org/abstracts/search?q=octreotide" title=" octreotide"> octreotide</a>, <a href="https://publications.waset.org/abstracts/search?q=imaging" title=" imaging "> imaging </a> </p> <a href="https://publications.waset.org/abstracts/34303/evaluation-of-the-radiolabelled-68ga-dotatoc-complex-in-adenocarcinoma-breast-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/34303.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">341</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2166</span> Evaluation of Tumor-Infiltrating Lymphocytes in Breast Carcinoma: Correlation with Molecular Subtypes and Clinicopathological Parameters</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Arundhathi%20S.">Arundhathi S.</a>, <a href="https://publications.waset.org/abstracts/search?q=Poongodi%20R."> Poongodi R.</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Tumor-infiltrating lymphocytes (TILs) are indicative of the local immune response against tumor proliferation and metastasis. Emerging as a significant marker of immune reactivity, TILs are utilized to evaluate prognostic outcomes across various malignancies, including colon, ovarian, lung, bladder, and breast cancers. In breast cancer (BC), TILs are particularly relevant for assessing tumor response to therapy in both adjuvant and neoadjuvant settings, with a prominent role in triple-negative breast cancer (TNBC), where they have been associated with improved outcomes. As such, TILs are recognized as an independent marker of favorable prognosis in several tumor types, underscoring their potential as a tool in personalized cancer therapy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=intratumoral%20TIL" title=" intratumoral TIL"> intratumoral TIL</a>, <a href="https://publications.waset.org/abstracts/search?q=stromal%20TIL" title=" stromal TIL"> stromal TIL</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20infiltrating%20lymphocytes" title=" tumor infiltrating lymphocytes"> tumor infiltrating lymphocytes</a> </p> <a href="https://publications.waset.org/abstracts/194529/evaluation-of-tumor-infiltrating-lymphocytes-in-breast-carcinoma-correlation-with-molecular-subtypes-and-clinicopathological-parameters" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/194529.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">8</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2165</span> High-Dose-Rate Brachytherapy for Cervical Cancer: The Effect of Total Reference Air Kerma on the Results of Single-Channel and Tri-Channel Applicators</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hossain%20A.">Hossain A.</a>, <a href="https://publications.waset.org/abstracts/search?q=Miah%20S."> Miah S.</a>, <a href="https://publications.waset.org/abstracts/search?q=Ray%20P.%20K."> Ray P. K.</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Single channel and tri-channel applicators are used in the traditional treatment of cervical cancer. Total reference air kerma (TRAK) and treatment outcomes in high-dose-rate brachytherapy for cervical cancer using single-channel and tri-channel applicators were the main objectives of this retrospective study. Material and Methods: Patients in the radiotherapy division who received brachytherapy, chemotherapy, and external radiotherapy (EBRT) using single and tri-channel applicators were the subjects of a retrospective cohort study from 2016 to 2020. All brachytherapy parameters, including TRAK, were calculated in accordance with the international protocol. The Kaplan Meier method was used to analyze survival rates using a log-rank test. Results and Discussions: Based on treatment times of 15.34 (10-20) days and 21.35 (6.5-28) days, the TRAK for the tri-channel applicator was 0.52 cGy.m² and for the single-channel applicator was 0.34 cGy.m². Based on TRAK, the rectum, bladder, and tumor had respective Pearson correlations of 0.082, 0.009, and 0.032. The 1-specificity and sensitivity were 0.70 and 0.30, respectively. At that time, AUC was 0.71. The log-rank test showed that tri-channel applicators had a survival rate of 95% and single-channel applicators had a survival rate of 85% (p=0.565). Conclusions: The relationship between TRAK and treatment duration and Pearson correlation for the tumor, rectum, and bladder suggests that TRAK should be taken into account for the proper operation of single channel and tri-channel applicators. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=single-channel" title="single-channel">single-channel</a>, <a href="https://publications.waset.org/abstracts/search?q=tri-channel" title=" tri-channel"> tri-channel</a>, <a href="https://publications.waset.org/abstracts/search?q=high%20dose%20rate%20brachytherapy" title=" high dose rate brachytherapy"> high dose rate brachytherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=cervical%20cancer" title=" cervical cancer"> cervical cancer</a> </p> <a href="https://publications.waset.org/abstracts/153993/high-dose-rate-brachytherapy-for-cervical-cancer-the-effect-of-total-reference-air-kerma-on-the-results-of-single-channel-and-tri-channel-applicators" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/153993.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">101</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2164</span> Up-regulation of KRT14 Promotes EMT in Basal Muscle-invasive Bladder Cancer through IGF2BP1/FTO Dependence on Methyladenosine-modified SNAI1</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Shirui%20Huang">Shirui Huang</a>, <a href="https://publications.waset.org/abstracts/search?q=Wei%20Chen"> Wei Chen</a>, <a href="https://publications.waset.org/abstracts/search?q=Chuanshu%20Huang"> Chuanshu Huang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Basal muscle-invasive bladder cancer (BMIBC) is considered one of the subtypes of BC with the highest metastatic rate and the poorest prognosis. Therefore, elucidating the mechanisms underlying BMIBC metastasis and identifying novel precision therapeutic targets are current research hotspots and challenges to cancer researchers. Through a series of in vitro and in vivo functional experiments, we have identified the crucial role of KRT14 in the high invasiveness and adverse prognosis of BMIBC. We found that the K294 site within the IGF2BP1-KH2 domain is responsible for reading the conserved genetic information carried by D226/E227 in the KRT14 nuclear export signal (NES). Activation of the KRT14-IGF2BP1 signaling axis is essential for IGF2BP1-mediated stabilization of SNAI1 mRNA through FTO modification. Additionally, IGF2BP1 forms a positive feedback loop by stabilizing its own mRNA, thereby accelerating the invasion and metastasis of BMIBC. Collectively, our study identifies the KRT14/IGF2BP1/FTO/Snail signaling axis as an essential regulatory mechanism associated with poor prognosis in BMIBC, providing a theoretical basis for KRT14 and its downstream regulated molecules as therapeutic targets for BMIBC and the development of corresponding targeted therapies. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=BMIBC" title="BMIBC">BMIBC</a>, <a href="https://publications.waset.org/abstracts/search?q=KRT4" title=" KRT4"> KRT4</a>, <a href="https://publications.waset.org/abstracts/search?q=IFGF2BP1" title=" IFGF2BP1"> IFGF2BP1</a>, <a href="https://publications.waset.org/abstracts/search?q=DNA%20methylation" title=" DNA methylation"> DNA methylation</a> </p> <a href="https://publications.waset.org/abstracts/194686/up-regulation-of-krt14-promotes-emt-in-basal-muscle-invasive-bladder-cancer-through-igf2bp1fto-dependence-on-methyladenosine-modified-snai1" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/194686.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">8</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2163</span> Gall Bladder Polyp Identified as Solitary RCC Metastasis 4 Years after Nephrectomy: An Unusual Case Report</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Gerard%20Bray">Gerard Bray</a>, <a href="https://publications.waset.org/abstracts/search?q=Arya%20Bahadori"> Arya Bahadori</a>, <a href="https://publications.waset.org/abstracts/search?q=Sachinka%20Ranasinghe"> Sachinka Ranasinghe</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Renal cell carcinoma (RCC) is among the top 10 most common cancers worldwide, where metastatic disease carries a poor prognosis. Herein, we present a 74-year-old male presenting with asymptomatic solitary metachronous metastasis to the gall bladder 4 years following nephrectomy for clear cell RCC. Solitary RCC metastasis to the gall bladder following nephrectomy is rarely reported in the literature and brings with it a clinical conundrum of whether surgical resection or systemic therapy should be utilized. In this case, surgical excision with cholecystectomy was employed without systemic therapy. We, therefore, contribute a rare and interesting case that highlights that metastasectomy of a solitary metastasis can improve survival according to current literature. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=renal%20cell%20carcinoma" title="renal cell carcinoma">renal cell carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=gall%20bladder%20metastasis" title=" gall bladder metastasis"> gall bladder metastasis</a>, <a href="https://publications.waset.org/abstracts/search?q=solitary%20metastasectomy" title=" solitary metastasectomy"> solitary metastasectomy</a>, <a href="https://publications.waset.org/abstracts/search?q=metachronous" title=" metachronous"> metachronous</a> </p> <a href="https://publications.waset.org/abstracts/145137/gall-bladder-polyp-identified-as-solitary-rcc-metastasis-4-years-after-nephrectomy-an-unusual-case-report" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/145137.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">172</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2162</span> The Many Faces of Cancer and Knowing When to Say Stop</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Diwei%20Lin">Diwei Lin</a>, <a href="https://publications.waset.org/abstracts/search?q=Amanda%20Jh.%20Tan"> Amanda Jh. Tan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> We present a very rare case of de novo large cell neuroendocrine carcinoma of the prostate (LCNEC) in an 84-year-old male on a background of high-grade, muscle-invasive transitional cell carcinoma of the bladder. While NE tumours account for 1% to 5% of all cases of prostate cancer and scattered NE cells can be found in 10% to 100% of prostate adenocarcinomas, pure LCNEC of the prostate is extremely rare. Most LCNEC of the prostate is thought to originate by clonal progression under the selection pressure of therapy and refractory to long-term hormonal treatment for adenocarcinoma of the prostate. De novo LCNEC is only described in case reports and is thought to develop via direct malignant transformation. Limited data in the English literature makes it difficult to accurately predict the prognosis of LCNEC of the prostate. However, current evidence suggesting that increasing NE differentiation in prostate adenocarcinoma is associated with a higher stage, high-grade disease, and a worse prognosis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=large%20cell%20neuroendocrine%20cancer" title="large cell neuroendocrine cancer">large cell neuroendocrine cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=prostate%20cancer" title=" prostate cancer"> prostate cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=refractory%20cancer" title=" refractory cancer"> refractory cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=medical%20and%20health%20sciences" title=" medical and health sciences"> medical and health sciences</a> </p> <a href="https://publications.waset.org/abstracts/10859/the-many-faces-of-cancer-and-knowing-when-to-say-stop" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/10859.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">421</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2161</span> In-House Fatty Meal Cholescintigraphy as a Screening Tool in Patients Presenting with Dyspepsia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Avani%20Jain">Avani Jain</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Shelley"> S. Shelley</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Indirani"> M. Indirani</a>, <a href="https://publications.waset.org/abstracts/search?q=Shilpa%20Kalal"> Shilpa Kalal</a>, <a href="https://publications.waset.org/abstracts/search?q=Jaykanth%20Amalachandran"> Jaykanth Amalachandran</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Aim: To evaluate the prevalence of gall bladder dysfunction in patients with dyspepsia using In-House fatty meal cholescintigraphy. Materials & Methods: This study is a prospective cohort study. 59 healthy volunteers with no dyspeptic complaints and negative ultrasound and endoscopy were recruited in study. 61 patients having complaint of dyspepsia for duration of more than 6 months were included. All of them underwent 99mTc-Mebrofenin fatty meal cholescintigraphy following a standard protocol. Dynamic acquisitions were acquired for 120 minutes with an In-House fatty meal being given at 45th minute. Gall bladder emptying kinetics was determined with gall bladder ejection fractions (GBEF) calculated at 30minutes, 45minutes and at 60 minutes (30min, 45min & 60 min). Standardization of fatty meal was done for volunteers. Receiver operating characteristic (ROC) analysis was used assess the diagnostic accuracy of 3 time points (30min, 45min & 60 min) used for measuring gall bladder emptying. On the basis of cut off derived from volunteers, the patients were assessed for gall bladder dysfunction. Results: In volunteers, the GBEF at 30 min was 74.42±8.26 % (mean ±SD), at 45 min was 82.61 ± 6.5 % and at 60 min was 89.37±4.48%, compared to patients where at 30min it was 33.73±22.87%, at 45 min it was 43.03±26.97% and at 60 min it was 51.85±29.60%. The lower limit of GBEF in volunteers at 30 min was 60%, 45 min was 69% and at 60 min was 81%. ROC analysis showed that area under curve was largest for 30 min GBEF (0.952; 95% CI = 0.914-0.989) and that all the 3 measures were statistically significant (p < 0.005). Majority of the volunteers had 74% of gall bladder emptying by 30 minutes; hence it was taken as an optimum cutoff time to assess gall bladder contraction. > 60% GBEF at 30 min post fatty meal was considered as normal and < 60% GBEF as indicative of gall bladder dysfunction. In patients, various causes for dyspepsia were identified: GB dysfunction (63.93%), Peptic ulcer (8.19 %), Gastroesophageal reflux disease (8.19%), Gastritis (4.91%). In 18.03% of cases GB dysfunction coexisted with other gastrointestinal conditions. The diagnosis of functional dyspepsia was made in 14.75% of cases. Conclusions: Gall bladder dysfunction contributes significantly to the causation of dyspepsia. It could coexist with various other gastrointestinal diseases. Fatty meal was well tolerated and devoid of any side effects. Many patients who are labeled as functional dyspeptics could actually have gall bladder dysfunction. Hence as an adjunct to ultrasound and endoscopy, fatty meal cholescintigraphy can also be used as a screening modality in characterization of dyspepsia. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=in-house%20fatty%20meal" title="in-house fatty meal">in-house fatty meal</a>, <a href="https://publications.waset.org/abstracts/search?q=choescintigraphy" title=" choescintigraphy"> choescintigraphy</a>, <a href="https://publications.waset.org/abstracts/search?q=dyspepsia" title=" dyspepsia"> dyspepsia</a>, <a href="https://publications.waset.org/abstracts/search?q=gall%20bladder%20ejection%20fraction" title=" gall bladder ejection fraction"> gall bladder ejection fraction</a>, <a href="https://publications.waset.org/abstracts/search?q=functional%20dyspepsia" title=" functional dyspepsia"> functional dyspepsia</a> </p> <a href="https://publications.waset.org/abstracts/13708/in-house-fatty-meal-cholescintigraphy-as-a-screening-tool-in-patients-presenting-with-dyspepsia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/13708.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">508</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2160</span> Photobleaching Kinetics and Epithelial Distribution of Hexylaminoleuilinate Induced PpIX in Rat Bladder Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sami%20El%20Khatib">Sami El Khatib</a>, <a href="https://publications.waset.org/abstracts/search?q=Agn%C3%A8s%20Leroux"> Agnès Leroux</a>, <a href="https://publications.waset.org/abstracts/search?q=Jean-Louis%20Merlin"> Jean-Louis Merlin</a>, <a href="https://publications.waset.org/abstracts/search?q=Fran%C3%A7ois%20Guillemin"> François Guillemin</a>, <a href="https://publications.waset.org/abstracts/search?q=Marie-Ange%20D%E2%80%99Hallewin"> Marie-Ange D’Hallewin</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Photodynamic therapy (PDT) is a treatment modality based on the cytotoxic effect occurring on the target tissues by interaction of a photosensitizer with light in the presence of oxygen. One of the major advances in PDT can be attributed to the use of topical aminolevulinic (ALA) to induce Protoporphyrin IX (PpIX) for the treatment of early stage cancers as well as diagnosis. ALA is a precursor of the heme synthesis pathway. Locally delivered to the target tissue ALA overcomes the negative feedback exerted by heme and promotes the transient formation of PpIX in situ to reach critical effective levels in cells and tissue. Whereas early steps of the heme pathway occur in the cytosol, PpIX synthesis is shown to be held in the mitochondrial membranes and PpIX fluorescence is expected to accumulate in close vicinity of the initial building site and to progressively diffuse to the neighboring cytoplasmic compartment or other lipophylic organelles. PpIX is known to be highly reactive and will be degraded when irradiated with light. PpIX photobleaching is believed to be governed by a singlet oxygen mediated mechanism in the presence of oxidized amino acids and proteins. PpIX photobleaching and subsequent spectral phototransformation were described widely in tumor cells incubated in vitro with ALA solution, or ex vivo in human and porcine mucosa superfused with hexylaminolevulinate (hALA). PpIX photobleaching was also studied in vivo, using animal models such as normal or tumor mice skin and orthotopic rat bladder model. Hexyl aminolevulinate a more potent lipophilic derivative of ALA was proposed as an adjunct to standard cystoscopy in the fluorescence diagnosis of bladder cancer and other malignancies. We have previously reported the effectiveness of hALA mediated PDT of rat bladder cancer. Although normal and tumor bladder epithelium exhibit similar fluorescence intensities after intravesical instillation of two hALA concentrations (8 and 16 mM), the therapeutic response at 8mM and 20J/cm2 was completely different from the one observed at 16mM irradiated with the same light dose. Where the tumor is destroyed, leaving the underlying submucosa and muscle intact after an 8 mM instillation, 16mM sensitization and subsequent illumination results in the complete destruction of the underlying bladder wall but leaves the tumor undamaged. The object of the current study is to try to unravel the underlying mechanism for this apparent contradiction. PpIX extraction showed identical amounts of photosensitizer in tumor bearing bladders at both concentrations. Photobleaching experiments revealed mono-exponential decay curves in both situations but with a two times faster decay constant in case of 16mM bladders. Fluorescence microscopy shows an identical fluorescence pattern for normal bladders at both concentrations and tumor bladders at 8mM with bright spots. Tumor bladders at 16 mM exhibit a more diffuse cytoplasmic fluorescence distribution. The different response to PDT with regard to the initial pro-drug concentration can thus be attributed to the different cellular localization. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=bladder%20cancer" title="bladder cancer">bladder cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=hexyl-aminolevulinate" title=" hexyl-aminolevulinate"> hexyl-aminolevulinate</a>, <a href="https://publications.waset.org/abstracts/search?q=photobleaching" title=" photobleaching"> photobleaching</a>, <a href="https://publications.waset.org/abstracts/search?q=confocal%20fluorescence%20microscopy" title=" confocal fluorescence microscopy"> confocal fluorescence microscopy</a> </p> <a href="https://publications.waset.org/abstracts/39348/photobleaching-kinetics-and-epithelial-distribution-of-hexylaminoleuilinate-induced-ppix-in-rat-bladder-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/39348.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">407</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2159</span> Dietary Vitamin D Intake and the Bladder Cancer Risk: A Pooled Analysis of Prospective Cohort Studies</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Iris%20W.%20A.%20Boot">Iris W. A. Boot</a>, <a href="https://publications.waset.org/abstracts/search?q=Anke%20Wesselius"> Anke Wesselius</a>, <a href="https://publications.waset.org/abstracts/search?q=Maurice%20P.%20Zeegers"> Maurice P. Zeegers</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Diet may play an essential role in the aetiology of bladder cancer (BC). Vitamin D is involved in various biological functions which have the potential to prevent BC development. Besides, vitamin D also influences the uptake of calcium and phosphorus , thereby possibly indirectly influencing the risk of BC. The aim of the present study was to investigate the relation between vitamin D intake and BC risk. Individual dietary data were pooled from three cohort studies. Food item intake was converted to daily intakes of vitamin D, calcium and phosphorus. Pooled multivariate hazard ratios (HRs), with corresponding 95% confidence intervals (CIs) were obtained using Cox-regression models. Analyses were adjusted for gender, age and smoking status (Model 1), and additionally for the food groups fruit, vegetables and meat (Model 2). Dose–response relationships (Model 1) were examined using a nonparametric test for trend. In total, 2,871 cases and 522,364 non-cases were included in the analyses. The present study showed an overall increased BC risk for high dietary vitamin D intake (HR: 1.14, 95% CI: 1.03-1.26). A similar increase BC risk with high vitamin D intake was observed among women and for the non-muscle invasive BC subtype, (HR: 1.41, 95% CI: 1.15-1.72, HR: 1.13, 95% CI: 1.01-1.27, respectively). High calcium intake decreased the BC risk among women (HR: 0.81, 95% CI: 0.67-0.97). A combined inverse effect on BC risk was observed for low vitamin D intake and high calcium intake (HR: 0.67, 95% CI: 0.48-0.93), while a positive effect was observed for high vitamin D intake in combination with low, moderate and high phosphorus (HR: 1.31, 95% CI: 1.09-1.59, HR: 1.17, 95% CI: 1.01-1.36, HR: 1.16, 95% CI: 1.03-1.31, respectively). Combining all nutrients showed a decreased BC risk for low vitamin D intake, high calcium and moderate phosphor intake (HR: 0.37, 95% CI: 0.18-0.75), and an increased BC risk for moderate intake of all the nutrients (HR: 1.18, 95% CI: 1.02-1.38), for high vitamin D and low calcium and phosphor intake (HR: 1.28, 95% CI: 1.01-1.62), and for moderate vitamin D and calcium and high phosphorus intake (HR: 1.27, 95% CI: 1.01-1.59). No significant dose-response analyses were observed. The findings of this study show an increased BC risk for high dietary vitamin D intake and a decreased risk for high calcium intake. Besides, the study highlights the importance of examining the effect of a nutrient in combination with complementary nutrients for risk assessment. Future research should focus on nutrients in a wider context and in nutritional patterns. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=bladder%20cancer" title="bladder cancer">bladder cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=nutritional%20oncology" title=" nutritional oncology"> nutritional oncology</a>, <a href="https://publications.waset.org/abstracts/search?q=pooled%20cohort%20analysis" title=" pooled cohort analysis"> pooled cohort analysis</a>, <a href="https://publications.waset.org/abstracts/search?q=vitamin%20D" title=" vitamin D"> vitamin D</a> </p> <a href="https://publications.waset.org/abstracts/152935/dietary-vitamin-d-intake-and-the-bladder-cancer-risk-a-pooled-analysis-of-prospective-cohort-studies" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/152935.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">84</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2158</span> Identification of the Target Genes to Increase the Immunotherapy Response in Bladder Cancer Patients using Computational and Experimental Approach</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sahar%20Nasr">Sahar Nasr</a>, <a href="https://publications.waset.org/abstracts/search?q=Lin%20Li"> Lin Li</a>, <a href="https://publications.waset.org/abstracts/search?q=Edwin%20Wang"> Edwin Wang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Bladder cancer (BLCA) is known as the 13th cause of death among cancer patients worldwide, and ~575,000 new BLCA cases are diagnosed each year. Urothelial carcinoma (UC) is the most prevalent subtype among BLCA patients, which can be categorized into muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC). Currently, various therapeutic options are available for UC patients, including (1) transurethral resection followed by intravesical instillation of chemotherapeutics or Bacillus Calmette-Guérin for NMIBC patients, (2) neoadjuvant platinum-based chemotherapy (NAC) plus radical cystectomy is the standard of care for localized MIBC patients, and (3) systematic chemotherapy for metastatic UC. However, conventional treatments may lead to several challenges for treating patients. As an illustration, some patients may suffer from recurrence of the disease after the first line of treatment. Recently, immune checkpoint therapy (ICT) has been introduced as an alternative treatment strategy for the first or second line of treatment in advanced or metastatic BLCA patients. Although ICT showed lucrative results for a fraction of BLCA patients, ~80% of patients were not responsive to it. Therefore, novel treatment methods are required to augment the ICI response rate within BLCA patients. It has been shown that the infiltration of T-cells into the tumor microenvironment (TME) is positively correlated with the response to ICT within cancerous patients. Therefore, the goal of this study is to enhance the infiltration of cytotoxic T-cells into TME through the identification of target genes within the tumor that are responsible for the non-T-cell inflamed TME and their inhibition. BLCA bulk RNA-sequencing data from The Cancer Genome Atlas (TCGA) and immune score for TCGA samples were used to determine the Pearson correlation score between the expression of different genes and immune score for each sample. The genes with strong negative correlations were selected (r < -0.2). Thereafter, the correlation between the expression of each gene and survival in BLCA patients was calculated using the TCGA data and Cox regression method. The genes that are common in both selected gene lists were chosen for further analysis. Afterward, BLCA bulk and single-cell RNA-sequencing data were ranked based on the expression of each selected gene and the top and bottom 25% samples were used for pathway enrichment analysis. If the pathways related to the T-cell infiltration (e.g., antigen presentation, interferon, or chemokine pathways) were enriched within the low-expression group, the gene was included for downstream analysis. Finally, the selected genes will be used to calculate the correlation between their expression and the infiltration rate of the activated CD+8 T-cells, natural killer cells and the activated dendric cells. A list of potential target genes has been identified and ranked based on the above-mentioned analysis and criteria. SUN-1 got the highest score within the gene list and other identified genes in the literature as benchmarks. In conclusion, inhibition of SUN1 may increase the tumor-infiltrating lymphocytes and the efficacy of ICI in BLCA patients. BLCA tumor cells with and without SUN-1 CRISPR/Cas9 knockout will be injected into the syngeneic mouse model to validate the predicted SUN-1 effect on increasing tumor-infiltrating lymphocytes. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=data%20analysis" title="data analysis">data analysis</a>, <a href="https://publications.waset.org/abstracts/search?q=gene%20expression%20analysis" title=" gene expression analysis"> gene expression analysis</a>, <a href="https://publications.waset.org/abstracts/search?q=gene%20identification" title=" gene identification"> gene identification</a>, <a href="https://publications.waset.org/abstracts/search?q=immunoinformatic" title=" immunoinformatic"> immunoinformatic</a>, <a href="https://publications.waset.org/abstracts/search?q=functional%20genomics" title=" functional genomics"> functional genomics</a>, <a href="https://publications.waset.org/abstracts/search?q=transcriptomics" title=" transcriptomics"> transcriptomics</a> </p> <a href="https://publications.waset.org/abstracts/143621/identification-of-the-target-genes-to-increase-the-immunotherapy-response-in-bladder-cancer-patients-using-computational-and-experimental-approach" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/143621.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">155</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2157</span> The Dose to Organs in Lumbar-Abdominal Computed Tomography Imaging Using TLD</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=M.%20Zehtabian">M. Zehtabian</a>, <a href="https://publications.waset.org/abstracts/search?q=Z.%20Molaiemanesh"> Z. Molaiemanesh</a>, <a href="https://publications.waset.org/abstracts/search?q=Z.%20Shafahi"> Z. Shafahi</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Papie"> M. Papie</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Zahraie%20Moghaddam"> M. Zahraie Moghaddam</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Mehralizadeh"> M. Mehralizadeh</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20R.%20Vahidi"> M. R. Vahidi</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Sina"> S. Sina</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The introduction of CT scans has been a great improvement in diagnosis of different diseases. However, this imaging modality can expose the patients to cumulative radiation doses which may increase the risks of some health problems like cancer. In this study, the dose delivered to different organs in lumbar-abdominal imaging was measured by putting the TLD-100, and TLD-100H chips inside the Alderson Rando phantom. The lumbar-abdominal image of the phantom was obtained, while TLD chips were inside the holes of the phantom. According to the results obtained in this study using TLD-100 chips, the average dose received by liver, bladder, rectum, kidneys, and uterus were found to be 12.9 mSv, 8.9 mSv, 10.1 mSv, 11.0 mSv, 11.2 mSv, and 10.5 mSv respectively, while the measurements performed by TLD-100H show that the average dose to liver, bladder, rectum, kidneys, and uterus were found to be 12.4 mSv, 9.2 mSv, 9.5 mSv, 10.5 mSv, 10.7 mSv, and 9.9 mSv respectively. The results of this study indicates that the dose measured by the TLD-100H chips are in close agreement with those obtained by TLD-100. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=CT%20scan" title="CT scan">CT scan</a>, <a href="https://publications.waset.org/abstracts/search?q=dose" title=" dose"> dose</a>, <a href="https://publications.waset.org/abstracts/search?q=TLD-100" title=" TLD-100"> TLD-100</a>, <a href="https://publications.waset.org/abstracts/search?q=diagnosis" title=" diagnosis"> diagnosis</a> </p> <a href="https://publications.waset.org/abstracts/12970/the-dose-to-organs-in-lumbar-abdominal-computed-tomography-imaging-using-tld" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/12970.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">635</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2156</span> Assessment of the Effect of Orally Administered Itopride on Gall Bladder Ejection Fraction by a Fatty Meal Cholescintigraphy in Patients with Diabetes</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Avani%20Jain">Avani Jain</a>, <a href="https://publications.waset.org/abstracts/search?q=Hasmukh%20Jain"> Hasmukh Jain</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Shelley"> S. Shelley</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Indirani"> M. Indirani</a>, <a href="https://publications.waset.org/abstracts/search?q=Shilpa%20Kalal"> Shilpa Kalal</a>, <a href="https://publications.waset.org/abstracts/search?q=Jayakanth%20Amalachandran"> Jayakanth Amalachandran</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Aim of the Study: To assess the effect of orally administered Itopride on gall bladder ejection fraction by fatty meal cholescintigraphy in patients with diabetes. Materials and Methods: Thirty patients (20 males, 10 females, mean age 46+10 yrs) with history of diabetes mellitus (mean duration 4.8+4.1 yrs, fasting blood glucose level 130+35 mg/dl and 2-hours post-prandial blood glucose level 196+76 mg/dl) and found to have gall bladder dysfunction on fatty-meal stimulated cholescintigraphy were selected for this study. These patients underwent a repeat cholescintigraphy similar to baseline study, with 50 mg of Itopride orally along with fatty meal. Pre- and post-Itopride GBEF were then compared to assess the effect of Itopride on gall bladder contraction. Results: Out of these 30 patients, 2 had dyskinetic, 4 had akinetic, 22 had moderately hypokinetic and the remaining 2 had hypokinetic gall bladder function in the baseline study with > 60% GBEF being taken as the normal value. Mean percentage of GBEF in the baseline study was 32%+13% and the mean percentage of GBEF in the post-Itopride study was 57%+17% with change in mean percentage of GBEF being 24%+21%. GBEF of the “baseline study” was significantly lower as compared to GBEF in the “post-Itopride study” (p < 0.05). Conclusion: Diabetic patients with biliary-type pain often tend to have impaired gallbladder function. Cholescintigraphy with fatty meal-stimulation is a simple, cheap and useful investigation for assessment of gallbladder dysfunction in these patients, before any structural changes occur within the lumen or wall of the gall bladder. Improvement in gallbladder ejection fraction after oral administration of a single dose of Itopride, a newer prokinetic drug with fewer side effects, as assessed by cholescintigraphy, provides enough evidence of future therapeutic response. Administration of Itopride, in therapeutic dosage, therefore may be expected to cause significant improvement in gallbladder ejection fraction and hence prolong stone formation within the gall bladder and also prevent the associated long term complications. Hence, based on scintigraphic evidence, Itopride may be recommended, by clinicians, for management of symptomatic diabetic patients having gallbladder dysfunction. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=itopride" title="itopride">itopride</a>, <a href="https://publications.waset.org/abstracts/search?q=gall%20bladder%20ejection%20fraction" title=" gall bladder ejection fraction"> gall bladder ejection fraction</a>, <a href="https://publications.waset.org/abstracts/search?q=fatty%20meal" title=" fatty meal"> fatty meal</a>, <a href="https://publications.waset.org/abstracts/search?q=cholescintigraphy" title=" cholescintigraphy"> cholescintigraphy</a>, <a href="https://publications.waset.org/abstracts/search?q=diabetes" title=" diabetes"> diabetes</a> </p> <a href="https://publications.waset.org/abstracts/13709/assessment-of-the-effect-of-orally-administered-itopride-on-gall-bladder-ejection-fraction-by-a-fatty-meal-cholescintigraphy-in-patients-with-diabetes" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/13709.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">425</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2155</span> Origin Variability of Superior Vesical Artery</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Waseem%20Al-Talalwah">Waseem Al-Talalwah</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The superior vesical artery usually arises directly from the anterior division of the internal iliac artery. It may arise from the umbilical artery as three or four branches to supply the upper and middle parts of bladder. Current study focuses on the different origins of the superior vesical artery to provide a sufficient data for surgeons to disease iatrogenic fault. The superior vesical artery arises directly from the anterior division of the internal iliac artery in 24.5% whereas it arises indirectly as from umbilical artery in 83.7%. Further, it may arise from any branch of the anterior division as from the utrine and obturator arteries in 6.1% and in 6.3% respectively. It also shares the origin of the internal pudendal and inferior glutyeal artery as it arises from the gluteopudendal trunk in 4.1%. The superior vesical artery arises as a single, double, triple and quadruple in 69.4%, 20.4%, 8.2% and 2% respectively. In case of cystectomy for bladder cancer, surgeons have to be aware of the origin variability of superior vesical artery to prevent post-surgical complication such as intra-pelvic bleeding. Also, the as intra-pelvic bleeding has to be expected in case of hysterectomy therefore a great caution of the vesical branches arising from uterine artery has to be considered. In case of aneurysm resection of inferior gluteal artery arising from the gluteopudendal trunk, the surgeons have to be careful of the vascular supply of urinary bladder coming from above and below this common trunk as from superior and inferior vesical arteries respectively. Therefore, present study increases the awareness of clinical significance of superior vesical artery origin for surgeons to minimise the iatroginc errors. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=superior%20vesical%20artery" title="superior vesical artery">superior vesical artery</a>, <a href="https://publications.waset.org/abstracts/search?q=anterior%20division" title=" anterior division"> anterior division</a>, <a href="https://publications.waset.org/abstracts/search?q=internal%20iliac" title=" internal iliac"> internal iliac</a>, <a href="https://publications.waset.org/abstracts/search?q=internal%20pudendal" title=" internal pudendal"> internal pudendal</a>, <a href="https://publications.waset.org/abstracts/search?q=inferior%20glutyeal" title=" inferior glutyeal"> inferior glutyeal</a>, <a href="https://publications.waset.org/abstracts/search?q=intra-pelvic%20bleeding" title=" intra-pelvic bleeding"> intra-pelvic bleeding</a>, <a href="https://publications.waset.org/abstracts/search?q=hysterectomy" title=" hysterectomy"> hysterectomy</a>, <a href="https://publications.waset.org/abstracts/search?q=cystectomy" title=" cystectomy"> cystectomy</a> </p> <a href="https://publications.waset.org/abstracts/30961/origin-variability-of-superior-vesical-artery" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/30961.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">392</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2154</span> Dosimetric Comparison of Conventional Plans versus Three Dimensional Conformal Simultaneously Integrated Boost Plans</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Shoukat%20Ali">Shoukat Ali</a>, <a href="https://publications.waset.org/abstracts/search?q=Amjad%20Hussain"> Amjad Hussain</a>, <a href="https://publications.waset.org/abstracts/search?q=Latif-ur-Rehman"> Latif-ur-Rehman</a>, <a href="https://publications.waset.org/abstracts/search?q=Sehrish%20Inam"> Sehrish Inam</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Radiotherapy plays an important role in the management of cancer patients. Approximately 50% of the cancer patients receive radiotherapy at one point or another during the course of treatment. The entire radiotherapy treatment of curative intent is divided into different phases, depending on the histology of the tumor. The established protocols are useful in deciding the total dose, fraction size, and numbers of phases. The objective of this study was to evaluate the dosimetric differences between the conventional treatment protocols and the three-dimensional conformal simultaneously integrated boost (SIB) plans for three different tumors sites (i.e. bladder, breast, and brain). A total of 30 patients with brain, breast and bladder cancers were selected in this retrospective study. All the patients were CT simulated initially. The primary physician contoured PTV1 and PTV2 in the axial slices. The conventional doses prescribed for brain and breast is 60Gy/30 fractions, and 64.8Gy/36 fractions for bladder treatment. For the SIB plans biological effective doses (BED) were calculated for 25 fractions. The two conventional (Phase I and Phase II) and a single SIB plan for each patient were generated on Eclipse™ treatment planning system. Treatment plans were compared and analyzed for coverage index, conformity index, homogeneity index, dose gradient and organs at risk doses.In both plans 95% of PTV volume received a minimum of 95% of the prescribe dose. Dose deviation in the optic chiasm was found to be less than 0.5%. There is no significant difference in lung V20 and heart V30 in the breast plans. In the rectum plans V75%, V50% and V25% were found to be less than 1.2% different. Deviation in the tumor coverage, conformity and homogeneity indices were found to be less than 1%. SIB plans with three dimensional conformal radiotherapy technique reduce the overall treatment time without compromising the target coverage and without increasing dose to the organs at risk. The higher dose per fraction may increase the late effects to some extent. Further studies are required to evaluate the late effects with the intention of standardizing the SIB technique for practical implementation. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=coverage%20index" title="coverage index">coverage index</a>, <a href="https://publications.waset.org/abstracts/search?q=conformity%20index" title=" conformity index"> conformity index</a>, <a href="https://publications.waset.org/abstracts/search?q=dose%20gradient" title=" dose gradient"> dose gradient</a>, <a href="https://publications.waset.org/abstracts/search?q=homogeneity%20index" title=" homogeneity index"> homogeneity index</a>, <a href="https://publications.waset.org/abstracts/search?q=simultaneously%20integrated%20boost" title=" simultaneously integrated boost"> simultaneously integrated boost</a> </p> <a href="https://publications.waset.org/abstracts/24055/dosimetric-comparison-of-conventional-plans-versus-three-dimensional-conformal-simultaneously-integrated-boost-plans" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/24055.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">476</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2153</span> Forecasting Cancers Cases in Algeria Using Double Exponential Smoothing Method</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Messis%20A.">Messis A.</a>, <a href="https://publications.waset.org/abstracts/search?q=Adjebli%20A."> Adjebli A.</a>, <a href="https://publications.waset.org/abstracts/search?q=Ayeche%20R."> Ayeche R.</a>, <a href="https://publications.waset.org/abstracts/search?q=Talbi%20M."> Talbi M.</a>, <a href="https://publications.waset.org/abstracts/search?q=Tighilet%20K."> Tighilet K.</a>, <a href="https://publications.waset.org/abstracts/search?q=Louardiane%20M."> Louardiane M.</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Cancers are the second cause of death worldwide. Prevalence and incidence of cancers is getting increased by aging and population growth. This study aims to predict and modeling the evolution of breast, Colorectal, Lung, Bladder and Prostate cancers over the period of 2014-2019. In this study, data were analyzed using time series analysis with double exponential smoothing method to forecast the future pattern. To describe and fit the appropriate models, Minitab statistical software version 17 was used. Between 2014 and 2019, the overall trend in the raw number of new cancer cases registered has been increasing over time; the change in observations over time has been increasing. Our forecast model is validated since we have good prediction for the period 2020 and data not available for 2021 and 2022. Time series analysis showed that the double exponential smoothing is an efficient tool to model the future data on the raw number of new cancer cases. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cancer" title="cancer">cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=time%20series" title=" time series"> time series</a>, <a href="https://publications.waset.org/abstracts/search?q=prediction" title=" prediction"> prediction</a>, <a href="https://publications.waset.org/abstracts/search?q=double%20exponential%20smoothing" title=" double exponential smoothing"> double exponential smoothing</a> </p> <a href="https://publications.waset.org/abstracts/164142/forecasting-cancers-cases-in-algeria-using-double-exponential-smoothing-method" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/164142.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">88</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2152</span> An Investigation of Tetraspanin Proteins’ Role in UPEC Infection</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Fawzyah%20Albaldi">Fawzyah Albaldi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Urinary tract infections (UTIs) are the most prevalent of infectious diseases and > 80% are caused by uropathogenic E. coli (UPEC). Infection occurs following adhesion to urothelial plaques on bladder epithelial cells, whose major protein constituent are the uroplakins (UPs). Two of the four uroplakins (UPIa and UPIb) are members of the tetraspanin superfamily. The UPEC adhesin FimH is known to interact directly with UPIa. Tetraspanins are a diverse family of transmembrane proteins that generally act as “molecular organizers” by binding different proteins and lipids to form tetraspanin enriched microdomains (TEMs). Previous work by our group has shown that TEMs are involved in the adhesion of many pathogenic bacteria to human cells. Adhesion can be blocked by tetraspanin-derived synthetic peptides, suggesting that tetraspanins may be valuable drug targets. In this study, we investigate the role of tetraspanins in UPEC adherence to bladder epithelial cells. Human bladder cancer cell lines (T24, 5637, RT4), commonly used as in-vitro models to investigate UPEC infection, along with primary human bladder cells, were used in this project. The aim was to establish a model for UPEC adhesion/infection with the objective of evaluating the impact of tetraspanin-derived reagents on this process. Such reagents could reduce the progression of UTI, particularly in patients with indwelling catheters. Tetraspanin expression on the bladder cells was investigated by q-PCR and flow cytometry, with CD9 and CD81 generally highly expressed. Interestingly, despite these cell lines being used by other groups to investigate FimH antagonists, uroplakin proteins (UPIa, UPIb and UPIII) were poorly expressed at the cell surface, although some were present intracellularly. Attempts were made to differentiate the cell lines, to induce cell surface expression of these UPs, but these were largely unsuccessful. Pre-treatment of bladder epithelial cells with anti-CD9 monoclonal antibody significantly decreased UPEC infection, whilst anti-CD81 had no effects. A short (15aa) synthetic peptide corresponding to the large extracellular region (EC2) of CD9 also significantly reduced UPEC adherence. Furthermore, we demonstrated specific binding of that fluorescently tagged peptide to the cells. CD9 is known to associate with a number of heparan sulphate proteoglycans (HSPGs) that have also been implicated in bacterial adhesion. Here, we demonstrated that unfractionated heparin (UFH)and heparin analogs significantly inhibited UPEC adhesion to RT4 cells, as did pre-treatment of the cells with heparinases. Pre-treatment with chondroitin sulphate (CS) and chondroitinase also significantly decreased UPEC adherence to RT4 cells. This study may shed light on a common pathogenicity mechanism involving the organisation of HSPGs by tetraspanins. In summary, although we determined that the bladder cell lines were not suitable to investigate the role of uroplakins in UPEC adhesion, we demonstrated roles for CD9 and cell surface proteoglycans in this interaction. Agents that target these may be useful in treating/preventing UTIs. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=UTIs" title="UTIs">UTIs</a>, <a href="https://publications.waset.org/abstracts/search?q=tspan" title=" tspan"> tspan</a>, <a href="https://publications.waset.org/abstracts/search?q=uroplakins" title=" uroplakins"> uroplakins</a>, <a href="https://publications.waset.org/abstracts/search?q=CD9" title=" CD9"> CD9</a> </p> <a href="https://publications.waset.org/abstracts/146875/an-investigation-of-tetraspanin-proteins-role-in-upec-infection" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/146875.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">103</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2151</span> Differential Diagnosis of an Asymptomatic Lesion in Contact with the Bladder</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Angelis%20P.%20Barlampas">Angelis P. Barlampas</a> </p> <p class="card-text"><strong>Abstract:</strong></p> PURPOSE: Presentation of an interesting finding in an asymptomatic patient. MATERIAL: A patient came at hospital because of dysuric complaints and after a urologist’s prescription of a US exam of the urogenital system. The simple ultrasound examination of the lower abdomen revealed a moderate hypertrophy of the prostate and a solitary large bladder stone. The kidneys were normal. Then, the patient underwent a CT scan, which depicted the bladder stone and, as an incidental finding, a cystic lesion in contact with the upper anterior right surface of the bladder, with mural calcifications. METHOD: Abdominal ultrasound and abdominal computed tomography before and after intravenous contrast administration. RESULTS: The repeated US exam showed a cylindrical cystic lesion with a double wall and two mural hyperechoic foci, with partial posterior shadowing. Blood flow was not recognized on color doppler. The CT exam confirmed the cystic-like anechoic lesion, in the right iliac fossa, with the presence of two foci of mural calcifications. The differential diagnosis includes cases of enteric cyst, intestinal duplication cyst, chronic abscess, urachal cyst, Meckel's diverticulum, bladder diverticulum, old hematoma, thrombosed vascular aneurysm, diverticular abscess, etc. The patient refused surgical removal and is being monitored by ultrasound. CONCLUSIONS: The careful examination of the wider peri-abdominal area, especially during the routine ultrasound examination, can contribute to the identification of important asymptomatic findings. The radiologist must not be solely focused in a certain area of examination, even if the clinical doctor asks so, but should give attention to the neighboring areas, too. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=enteric%20cyst" title="enteric cyst">enteric cyst</a>, <a href="https://publications.waset.org/abstracts/search?q=US" title=" US"> US</a>, <a href="https://publications.waset.org/abstracts/search?q=CT" title=" CT"> CT</a>, <a href="https://publications.waset.org/abstracts/search?q=urogenital%20tract" title=" urogenital tract"> urogenital tract</a>, <a href="https://publications.waset.org/abstracts/search?q=miscellaneous%20findings" title=" miscellaneous findings"> miscellaneous findings</a> </p> <a href="https://publications.waset.org/abstracts/170430/differential-diagnosis-of-an-asymptomatic-lesion-in-contact-with-the-bladder" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/170430.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">56</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=bladder%20cancer&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=bladder%20cancer&page=3">3</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=bladder%20cancer&page=4">4</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=bladder%20cancer&page=5">5</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=bladder%20cancer&page=6">6</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=bladder%20cancer&page=7">7</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=bladder%20cancer&page=8">8</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=bladder%20cancer&page=9">9</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=bladder%20cancer&page=10">10</a></li> <li class="page-item disabled"><span class="page-link">...</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=bladder%20cancer&page=72">72</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=bladder%20cancer&page=73">73</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=bladder%20cancer&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>